Tempest Therapeutics Unveils Strong Clinical Data for Amezalpat & TPST-2003, Secures Phase 3 Regulatory Alignment

summarizeSummary

Tempest Therapeutics announced strong clinical data for its Amezalpat HCC program, securing regulatory agreement for Phase 3, and positive Phase 1/2a data for its TPST-2003 CAR-T therapy, alongside a partner-funded pipeline strategy.

check_boxKey Events

• Amezalpat (HCC) Phase 2 Data & Phase 3 Regulatory Alignment

  The Amezalpat program for hepatocellular carcinoma (HCC) showed superior overall survival (HR 0.65) and objective response rates in its Phase 2 randomized study. The company has secured FDA Fast Track and Orphan Drug Designations, and reached agreement with FDA, EMA, and NMPA on the pivotal Phase 3 study design.

• TPST-2003 (rrMM) Phase 1/2a Clinical Data

  The TPST-2003 CD19/BCMA Dual CAR-T therapy for relapsed/refractory multiple myeloma (rrMM) with extramedullary disease (EMD) demonstrated a 100% objective response rate and 88.9% sCR/CR in hematological response, with a favorable safety profile in its Phase 1/2a trial. A China BLA submission is planned for 2027.

• Partner-Funded Pipeline Development

  Tempest Therapeutics is advancing a diversified oncology pipeline with significant partner funding, including TPST-1495 (NCI-funded Phase 2) and several CAR-T programs (TPST-2003, TPST-2206, TPST-3003, TPST-3206, TPST-4003) in China, funded by Novatim Immune Therapeutics. This strategy de-risks development and extends operational runway.

auto_awesomeAnalysis

Tempest Therapeutics has released a comprehensive corporate presentation detailing significant positive clinical data and regulatory progress for its oncology pipeline. The Amezalpat program, targeting hepatocellular carcinoma (HCC), demonstrated superior overall survival (HR 0.65) and objective response rates in its Phase 2 randomized study, leading to FDA Fast Track and Orphan Drug Designations, and agreement with FDA, EMA, and NMPA on a pivotal Phase 3 study design. This regulatory alignment and strong data significantly de-risk the program. Additionally, the TPST-2003 CAR-T therapy for relapsed/refractory multiple myeloma (rrMM) showed compelling Phase 1/2a results, including a 100% objective response rate and favorable safety profile, with plans for a China BLA submission in 2027. The company's strategy of partner-funded development for multiple programs, including TPST-1495 (NCI-funded Phase 2) and several Novatim-funded programs in China, is crucial for a micro-cap biotech, extending its operational runway and enabling pipeline advancement. This positive update follows recent highly dilutive financing and a change of control, suggesting the company is now executing on its pipeline to create shareholder value.